Journal
PHARMACEUTICS
Volume 13, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics13060776
Keywords
estrogen-related receptor gamma; inverse agonist; liquid chromatography-tandem mass spectrometry; metabolite identification; metabolomics
Categories
Funding
- National Research Foundation of Korea, Ministry of Science and ICT, Republic of Korea [NRF-2019R1A2C1008713]
- National Research Foundation of Korea, Ministry of Health & Welfare, Republic of Korea [A111345]
Ask authors/readers for more resources
DN203368 is a 4-hydroxy tamoxifen analog and a dual inverse agonist of ERR beta/gamma, potentially targeting metabolic diseases. In vitro metabolism of the compound in rat and human liver microsomes was studied using high-resolution mass spectrometry and metabolomic approaches, revealing different metabolites and pathways in the two species. This study suggests that non-targeted metabolomics with multivariate analysis may be more efficient for drug metabolite identification than conventional methods, aiding in understanding the pharmacokinetics and metabolism of DN203368 in animals and humans.
DN203368 ((E)-3-[1-(4-[4-isopropylpiperazine-1-yl]phenyl) 3-methyl-2-phenylbut-1-en-1-yl] phenol) is a 4-hydroxy tamoxifen analog that is a dual inverse agonist of estrogen-related receptor beta/gamma (ERR beta/gamma). ERR gamma is an orphan nuclear receptor that plays an important role in development and homeostasis and holds potential as a novel therapeutic target in metabolic diseases such as diabetes mellitus, obesity, and cancer. ERR beta is also one of the orphan nuclear receptors critical for many biological processes, such as development. We investigated the in vitro metabolism of DN203368 by conventional and metabolomic approaches using high-resolution mass spectrometry. The compound (100 mu M) was incubated with rat and human liver microsomes in the presence of NADPH. In the metabolomic approach, the m/z value and retention time information obtained from the sample and heat-inactivated control group were statistically evaluated using principal component analysis and orthogonal partial least-squares discriminant analysis. Significant features responsible for group separation were then identified using tandem mass spectra. Seven metabolites of DN203368 were identified in rat liver microsomes and the metabolic pathways include hydroxylation (M1-3), N-oxidation (M4), N-deisopropylation (M5), N,N-dealkylation (M6), and oxidation and dehydrogenation (M7). Only five metabolites (M2, M3, and M5-M7) were detected in human liver microsomes. In the conventional approach using extracted ion monitoring for values of mass increase or decrease by known metabolic reactions, only five metabolites (M1-M5) were found in rat liver microsomes, whereas three metabolites (M2, M3, and M5) were found in human liver microsomes. This study revealed that nontargeted metabolomics combined with high-resolution mass spectrometry and multivariate analysis could be a more efficient tool for drug metabolite identification than the conventional approach. These results might also be useful for understanding the pharmacokinetics and metabolism of DN203368 in animals and humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available